Table 2.
Candidate biomarker TOP2A and SIRT1 expression according to histological subtype, grading and AJCC stage. The table shows the number and percentage of patients with high TOP2A and SIRT1 expression.
| Histological Subtype | Total | TOP2A | SIRT1 | ||
|---|---|---|---|---|---|
| n | n | % | n | % | |
| UPS | 55 | 31 | 56 | 37 | 67 |
| Leiomyosarcoma | 30 | 12 | 40 | 17 | 57 |
| Synovial Sarcoma | 20 | 13 | 65 | 15 | 75 |
| Liposarcoma | 35 | 11 | 31 | 19 | 54 |
| Angiosarcoma | 5 | 2 | 40 | 3 | 60 |
| MPNST | 9 | 6 | 67 | 3 | 33 |
| Other | 13 | 4 | 31 | 6 | 46 |
| Grading | n | n | % | n | % |
| G2 | 84 | 28 | 33 | 45 | 54 |
| G3 | 83 | 51 | 61 | 55 | 66 |
| AJCC Stage | n | n | % | n | % |
| Stage II | 31 | 16 | 52 | 21 | 68 |
| Stage III | 118 | 55 | 47 | 70 | 59 |
PS—undifferentiated pleomorphic sarcoma; MPNST—malignant peripheral nerve sheath tumor. Other—3 Chondrosarcomas, 4 Myxofibrosarcomas, 1 Alveolar sarcoma, 2 Carcinosarcomas, 1 Rhabdomyosarcoma, 2 malignant SFT (solitary fibrous tumor).